GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Harbin Gloria Pharmaceuticals Co Ltd (SZSE:002437) » Definitions » Equity-to-Asset

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Equity-to-Asset : 0.59 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Harbin Gloria Pharmaceuticals Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Harbin Gloria Pharmaceuticals Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥1,808 Mil. Harbin Gloria Pharmaceuticals Co's Total Assets for the quarter that ended in Mar. 2024 was ¥3,080 Mil. Therefore, Harbin Gloria Pharmaceuticals Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.59.

The historical rank and industry rank for Harbin Gloria Pharmaceuticals Co's Equity-to-Asset or its related term are showing as below:

SZSE:002437' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.24   Med: 0.45   Max: 0.62
Current: 0.59

During the past 13 years, the highest Equity to Asset Ratio of Harbin Gloria Pharmaceuticals Co was 0.62. The lowest was 0.24. And the median was 0.45.

SZSE:002437's Equity-to-Asset is ranked better than
51.93% of 1086 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs SZSE:002437: 0.59

Harbin Gloria Pharmaceuticals Co Equity-to-Asset Historical Data

The historical data trend for Harbin Gloria Pharmaceuticals Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harbin Gloria Pharmaceuticals Co Equity-to-Asset Chart

Harbin Gloria Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.41 0.40 0.40 0.53

Harbin Gloria Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.46 0.50 0.53 0.59

Competitive Comparison of Harbin Gloria Pharmaceuticals Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Harbin Gloria Pharmaceuticals Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harbin Gloria Pharmaceuticals Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Harbin Gloria Pharmaceuticals Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Harbin Gloria Pharmaceuticals Co's Equity-to-Asset falls into.



Harbin Gloria Pharmaceuticals Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Harbin Gloria Pharmaceuticals Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1661.773/3152.45
=0.53

Harbin Gloria Pharmaceuticals Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=1808.476/3079.865
=0.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harbin Gloria Pharmaceuticals Co  (SZSE:002437) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Harbin Gloria Pharmaceuticals Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Harbin Gloria Pharmaceuticals Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Harbin Gloria Pharmaceuticals Co (SZSE:002437) Business Description

Traded in Other Exchanges
N/A
Address
Beijing Road No 29, Harbin Economic and Technological Development Zone, Harbin, CHN, 150025
Harbin Gloria Pharmaceuticals Co Ltd is a tech biopharmaceutical enterprise. It is engaged in the research, development, production, and sale of pharmaceutical products primarily in China. The company offers cardiovascular drugs; cardiac cerebrovascular medication; vitamins and minerals; urinary tract drugs; urinary system medication; anti-tumor medication; endocrine system drugs; anti-infective drugs; digestive system medication; respiratory medication; and other medications.
Executives
Guo Yun Pei Independent director
Wang Yu Supervisors
Yang Hong Bing Director
Diao Xiu Qiang Directors, executives
Liu Yue Yin Securities Affairs Representative
Guo Lei Feng Directors, Directors, and Executives
Li Jun Ling Director
Yang Hai Feng Executives
Zhang Su Mei Supervisors
Zhu Ji Man Director

Harbin Gloria Pharmaceuticals Co (SZSE:002437) Headlines

No Headlines